Literature DB >> 30630979

Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis.

Almuth Hoffmann1, Sascha Dietrich2, Susanne Hain3, Michael Rieger4, Ute Hegenbart2, Leopold Sellner2, Anthony D Ho2, Carsten Müller-Tidow2, Peter Dreger2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30630979      PMCID： PMC6601102          DOI： 10.3324/haematol.2018.209486

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.

Authors:  Isabelle Krämer; Stephan Stilgenbauer; Sascha Dietrich; Sebastian Böttcher; Matthias Zeis; Michael Stadler; Jörg Bittenbring; Lutz Uharek; Christof Scheid; Ute Hegenbart; Anthony Ho; Michael Hallek; Michael Kneba; Norbert Schmitz; Hartmut Döhner; Peter Dreger
Journal:  Blood       Date:  2017-07-17       Impact factor: 22.113

2.  Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  J R Passweg; H Baldomero; P Bader; C Bonini; S Cesaro; P Dreger; R F Duarte; C Dufour; J Kuball; D Farge-Bancel; A Gennery; N Kröger; F Lanza; A Nagler; A Sureda; M Mohty
Journal:  Bone Marrow Transplant       Date:  2016-11-07       Impact factor: 5.483

3.  Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.

Authors:  Peter Dreger; Mauricette Michallet; Paul Bosman; Sascha Dietrich; Mohamad Sobh; Ariane Boumendil; Arnon Nagler; Christof Scheid; Jan Cornelissen; Dietger Niederwieser; Lutz Müller; Elizabeth Vandenberghe; Ilaria Scortechini; Helene Schoemans; Niels S Andersen; Jürgen Finke; Domenico Russo; Per Ljungman; Jakob Passweg; Michel van Gelder; Nadira Durakovic; Helene Labussiere-Wallet; Tobias Berg; Gerald Wulf; Wolfgang Bethge; Donald Bunjes; Stefan Stilgenbauer; Maria Elisa Canepari; Michel Schaap; Christopher P Fox; Nicolaus Kröger; Silvia Montoto; Johannes Schetelig
Journal:  Bone Marrow Transplant       Date:  2018-05-04       Impact factor: 5.483

4.  Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.

Authors:  S Böttcher; S Stilgenbauer; R Busch; M Brüggemann; T Raff; C Pott; K Fischer; G Fingerle-Rowson; H Döhner; M Hallek; M Kneba; M Ritgen
Journal:  Leukemia       Date:  2009-07-30       Impact factor: 11.528

Review 5.  Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Authors:  Peter Dreger; Johannes Schetelig; Niels Andersen; Paolo Corradini; Michel van Gelder; John Gribben; Eva Kimby; Mauricette Michallet; Carol Moreno; Stephan Stilgenbauer; Emili Montserrat
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

Review 6.  High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

Authors:  Peter Dreger; Paolo Ghia; Johannes Schetelig; Michel van Gelder; Eva Kimby; Mauricette Michallet; Carol Moreno; Tadeusz Robak; Stephan Stilgenbauer; Emili Montserrat
Journal:  Blood       Date:  2018-07-11       Impact factor: 22.113

7.  Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Authors:  Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Peter Hillmen; John F Seymour; Steven Coutre; Wojciech Jurczak; Stephen P Mulligan; Anna Schuh; Sarit Assouline; Clemens-Martin Wendtner; Andrew W Roberts; Matthew S Davids; Johannes Bloehdorn; Talha Munir; Sebastian Böttcher; Lang Zhou; Ahmed Hamed Salem; Monali Desai; Brenda Chyla; Jennifer Arzt; Su Young Kim; Maria Verdugo; Gary Gordon; Michael Hallek; William G Wierda
Journal:  J Clin Oncol       Date:  2018-05-01       Impact factor: 44.544

8.  Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

Authors:  Susan O'Brien; Richard R Furman; Steven Coutre; Ian W Flinn; Jan A Burger; Kristie Blum; Jeff Sharman; William Wierda; Jeffrey Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Ying Luan; Danelle F James; Alvina D Chu; John C Byrd
Journal:  Blood       Date:  2018-02-02       Impact factor: 25.476
  8 in total
  4 in total

1.  Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.

Authors:  Lindsey E Roeker; Peter Dreger; Jennifer R Brown; Oscar B Lahoud; Toby A Eyre; Danielle M Brander; Alan Skarbnik; Catherine C Coombs; Haesook T Kim; Matthew Davids; Steven T Manchini; Gemlyn George; Nirav Shah; Timothy J Voorhees; Kim H Orchard; Harriet S Walter; Arvind K Arumainathan; Andrea Sitlinger; Jae H Park; Mark B Geyer; Andrew D Zelenetz; Craig S Sauter; Sergio A Giralt; Miguel-Angel Perales; Anthony R Mato
Journal:  Blood Adv       Date:  2020-08-25

2.  Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial.

Authors:  Olivier Tournilhac; Magali Le Garff-Tavernier; Stéphanie Nguyen Quoc; Edouard Forcade; Patrice Chevallier; Faezeh Legrand-Izadifar; Gandhi Laurent Damaj; David Michonneau; Cécile Tomowiak; Cécile Borel; Corentin Orvain; Pascal Turlure; Rabah Redjou; Gaëlle Guillerm; Laure Vincent; Celestine Simand; Richard Lemal; Claire Quiney; Patricia Combes; Bruno Pereira; Laure Calvet; Aurélie Cabrespine; Jacques-Olivier Bay; Véronique Leblond; Nathalie Dhédin; French Innovative Leukemia Organization Filo; Société Francophone de Greffe De Moelle Et de Thérapie Cellulaire Sfgm-Tc
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

3.  Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.

Authors:  Haesook T Kim; Conner J Shaughnessy; Sharmila C Rai; Carol Reynolds; Vincent T Ho; Corey Cutler; John Koreth; Mahasweta Gooptu; Rizwan Romee; Sarah Nikiforow; Philippe Armand; Edwin P Alyea; Joseph H Antin; Catherine J Wu; Robert J Soiffer; Jerome Ritz; Jennifer R Brown
Journal:  Blood Adv       Date:  2020-09-08

Review 4.  Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.

Authors:  Lina van der Straten; Paul J Hengeveld; Arnon P Kater; Anton W Langerak; Mark-David Levin
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.